

St John's DermAcademy Podcasts by Dr Sarah Drummond

Episode 15: Immunobullous disorders - Part 2: Pemphigus vulgaris



Dr Thomas Tull
BSc (hons), MBBS, PhD, MRCP (UK)

Consultant Dermatologist, St John's Institute of Dermatology
Guy's and St Thomas' NHS Foundation Trust

In this episode we discuss...

- The clinical features of pemphigus vulgaris and other variants of pemphigus.
- The step-wise management of pemphigus vulgaris including an approach to managing severe disease and the use of rituximab and intravenous immunoglobulin.

Resources and further reading:

- British Association of Dermatologists' guidelines for the management of pemphigus vulgaris, 2017 (<https://onlinelibrary.wiley.com/doi/full/10.1111/bjd.15930>)
- European guidelines for the management of pemphigus vulgaris and foliaceous initiated by the European Academy of Dermatology and Venereology, 2020 (<https://onlinelibrary.wiley.com/doi/full/10.1111/jdv.16752>)
- Rituximab and Covid-19 Risk – a single-centre cohort study ([https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913\(23\)00004-8/fulltext](https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(23)00004-8/fulltext))
- Phase 2 Study of efficacy and safety of Rilzabrutinib for patients with pemphigus vulgaris (<https://pubmed.ncbi.nlm.nih.gov/35686647/>)
- Phase 2 Study of the use of Efgartigimod for patients with pemphigus vulgaris and foliaceous (<https://pubmed.ncbi.nlm.nih.gov/34608631/>)

Disclosure: Dr. Tull provides consultancy services for Argenx who market Efgartigimod, which has been referenced in Part 1 and 2 of this series.